TELO · Telomir Pharmaceuticals, Inc. · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the issuance date of this Report.”View the 10-Q filed Aug 13, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-05-21 | Aminov Erez |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Non-Qualified Stock Options (right to buy) (Direct)
The reporting person agreed to cancellation of options granted to him on 08/27/2024 and 05/27/2025, in exchange for new options having a lower exercise price. The options are fully exercisable. |
Non-Qualified Stock Options (right to buy)
|
2,000,000 |
| 2026-05-21 | Del Giudice Matthew Paul |
Director |
Other↓
Filing footnotes — Incentive Stock Options (right to buy) (Direct)
The reporting person agreed to cancellation of the option granted to him on 08/27/2024, in exchange for a new option having a lower exercise price. |
Incentive Stock Options (right to buy)
|
25,000 |
| 2026-05-21 | MacPherson Edward Clouston |
Director |
Award↑
Filing footnotes — Incentive Stock Options (right to buy) (Direct)
The reporting person agreed to cancellation of the option granted to him on 08/27/2024, in exchange for a new option having a lower exercise price. The options are fully exercisable. |
Incentive Stock Options (right to buy)
|
25,000 |
| 2026-05-21 | Whalen Matthew Pratt |
Director |
Other↓
Filing footnotes — Incentive Stock Options (right to buy) (Direct)
The reporting person agreed to cancellation of the option granted to him on 08/27/2024, in exchange for a new option having a lower exercise price. |
Incentive Stock Options (right to buy)
|
25,000 |
| 2026-05-21 | MacPherson Edward Clouston |
Director |
Other↓
Filing footnotes — Incentive Stock Options (right to buy) (Direct)
The reporting person agreed to cancellation of the option granted to him on 08/27/2024, in exchange for a new option having a lower exercise price. |
Incentive Stock Options (right to buy)
|
25,000 |
| 2026-05-21 | Whalen Matthew Pratt |
Director |
Award↑
Filing footnotes — Incentive Stock Options (right to buy) (Direct)
The reporting person agreed to cancellation of the option granted to him on 08/27/2024, in exchange for a new option having a lower exercise price. The options are fully exercisable. |
Incentive Stock Options (right to buy)
|
25,000 |
| 2026-05-21 | Aminov Erez |
Director, Chief Executive Officer |
Other↓
Filing footnotes — Incentive Stock Options (right to buy) (Direct)
The reporting person agreed to cancellation of options granted to him on 08/27/2024 and 05/27/2025, in exchange for new options having a lower exercise price. |
Incentive Stock Options (right to buy)
|
1,960,170 |
| 2026-05-21 | Aminov Erez |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Incentive Stock Options (right to buy) (Direct)
The reporting person agreed to cancellation of options granted to him on 08/27/2024 and 05/27/2025, in exchange for new options having a lower exercise price. The options are fully exercisable. |
Incentive Stock Options (right to buy)
|
1,960,170 |
| 2026-05-21 | Aminov Erez |
Director, Chief Executive Officer |
Other↓
Filing footnotes — Non-Qualified Stock Options (right to buy) (Direct)
The reporting person agreed to cancellation of options granted to him on 08/27/2024 and 05/27/2025, in exchange for new options having a lower exercise price. |
Non-Qualified Stock Options (right to buy)
|
2,000,000 |
| 2026-05-21 | Del Giudice Matthew Paul |
Director |
Award↑
Filing footnotes — Incentive Stock Options (right to buy) (Direct)
The reporting person agreed to cancellation of the option granted to him on 08/27/2024, in exchange for a new option having a lower exercise price. The options are fully exercisable. |
Incentive Stock Options (right to buy)
|
25,000 |
| 2026-04-22 | Aminov Erez |
Director, Chief Executive Officer |
Other↑
Filing footnotes — Common Stock (Direct)
The shares of common stock, no par value of the Issuer issued to the Reporting Person are in exchange for the Reporting Person's shares of TELI Pharmaceuticals, Inc. ("TELI") in connection with the Issuer's acquisition of TELI. |
Common Stock
|
7,319,710 |
| 2026-04-16 | Del Giudice Matthew Paul |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Options (right to buy) (Direct)
The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on April 16, 2026. The stock options were issued to the Reporting Person on April 16, 2026, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). All of the options vested immediately upon issuance. |
Non-Qualified Stock Options (right to buy)
|
50,000 |
| 2026-04-16 | MacPherson Edward Clouston |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Options (right to buy) (Direct)
The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on April 16, 2026. The stock options were issued to the Reporting Person on April 16, 2026, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). All of the options vested immediately upon issuance. |
Non-Qualified Stock Options (right to buy)
|
50,000 |
| 2026-04-16 | Whalen Matthew Pratt |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Options (right to buy) (Direct)
The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on April 16, 2026. The stock options were issued to the Reporting Person on April 16, 2026, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). All of the options vested immediately upon issuance. |
Non-Qualified Stock Options (right to buy)
|
50,000 |
| 2025-05-28 | Aminov Erez |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Restricted Stock Units (RSUs) (Direct)
Each restricted stock unit represents a right to receive one share of Issuer's common stock. The RSUs were issued to the Reporting Person on May 28, 2025, pursuant to a grant under the Plan. The RSUs are fully vested as of the date of grant. Each restricted stock unit represents a right to receive one share of Issuer's common stock. |
Restricted Stock Units (RSUs)
|
400,000 |
| 2025-05-28 | Aminov Erez |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Non-Qualified Options (Direct)
The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on May 27, 2025. The stock options were issued to the Reporting Person on May 28, 2025, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). The stock options are fully vested as of the date of grant. |
Non-Qualified Options
|
2,000,000 |
| 2024-11-21 | Bay Shore Trust |
10% Owner |
Gift↓
Filing footnotes — Common Stock (right to buy) (Indirect)
Bona Fide Gift. No compensation was given to the donor for the gifting of securities. These securities are owned directly by the Bay Shore Trust (the "Trust"), a 10% owner of the Issuer, and indirectly by Brian McNulty ("Mr. McNulty") as trustee of the Trust. Mr. McNulty disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Common Stock (right to buy)
(I)
|
100,000 |
| 2024-08-27 | Jerman Michael Allen |
Director |
Award↑
Filing footnotes — Incentive Stock Options (right to buy) (Direct)
The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 26, 2024. The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). Fifty percent of the stock options vested immediately upon issuance and the remaining fifty percent of the stock options are to vest on February 26, 2025. |
Incentive Stock Options (right to buy)
|
25,000 |
| 2024-08-27 | Aminov Erez |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Incentive Stock Options (right to buy) (Direct)
The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 26, 2024. The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). Fifty percent of the stock options vested immediately upon issuance and the remaining fifty percent of the stock options are to vest on February 26, 2025. |
Incentive Stock Options (right to buy)
|
1,960,170 |
| 2024-08-27 | Yanez Michelle |
Chief Financial Officer |
Award↑
Filing footnotes — Incentive Stock Options (right to buy) (Direct)
The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 26, 2024. The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50,000 stock options of such grant shall vest, respectively, on each of February 26, 2025, August 26, 2025, February 26, 2026 and August 26, 2026. |
Incentive Stock Options (right to buy)
|
200,000 |
| 2024-08-27 | MacPherson Edward Clouston |
Director |
Award↑
Filing footnotes — Incentive Stock Options (right to buy) (Direct)
The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 26, 2024. The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). Fifty percent of the stock options vested immediately upon issuance and the remaining fifty percent of the stock options are to vest on February 26, 2025. |
Incentive Stock Options (right to buy)
|
25,000 |
| 2024-08-27 | Whalen Matthew Pratt |
Director |
Award↑
Filing footnotes — Incentive Stock Options (right to buy) (Direct)
The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 26, 2024. The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). Fifty percent of the stock options vested immediately upon issuance and the remaining fifty percent of the stock options are to vest on February 26, 2025. |
Incentive Stock Options (right to buy)
|
25,000 |
| 2024-08-27 | Del Giudice Matthew Paul |
Director |
Award↑
Filing footnotes — Incentive Stock Options (right to buy) (Direct)
The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 26, 2024. The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). Fifty percent of the stock options vested immediately upon issuance and the remaining fifty percent of the stock options are to vest on February 26, 2025. |
Incentive Stock Options (right to buy)
|
25,000 |
| 2024-08-19 | Aminov Erez |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the sale of common stock that should have been reported on Form 4. |
Common Stock
|
200 |
| 2024-08-19 | Aminov Erez |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the sale of common stock that should have been reported on Form 4. |
Common Stock
|
200 |
| 2024-02-13 | Bay Shore Trust |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
These securities are owned directly by the Bay Shore Trust (the "Trust"), a 10% owner of the Issuer, and indirectly by Brian McNulty ("Mr. McNulty") as trustee of the Trust. Mr. McNulty disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
49,000 |
| 2024-02-13 | Bay Shore Trust |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
These securities are owned directly by a trust for which Mr. McNulty serves as trustee. Mr. McNulty disclaims beneficial ownership of the reported securities because he is deemed to hold these securities only because of his role as Trustee and does not have any pecuniary interest in such securities. |
Common Stock
(I)
|
49,000 |
| 2024-02-13 | Bay Shore Trust |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
These securities are owned directly by the MIRALOGX, LLC, of which the Trust holds all of the membership interests, and indirectly by Mr. McNulty as trustee of the Trust. Mr. McNulty disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
40,000 |